ORAL III GENERATION CEPHALOSPORIN CEFTIBUTEN IN TREATMENT OF ACUTE TONSILLOPHARYNGITIS AND OTITIS
https://doi.org/10.15690/vsp.v11i2.228
Abstract
Tonsillopharyngitis is a common multietiological infectious disease, more often caused by streptococci infection. The development and adoption of oral III generation cephalosporins into clinical practice significantly widened the possibilities of treatment of inflammatoryinfectious diseases, including tonsillopharyngitis. One of the III generation cephalosporins is Ceftibuten (Cedax) — a drug with b-lactam properties, which inhibits bacterial peptidoglycan synthesis. It has relatively long post-antibiotic effect, characterized by high activity in point of majority of enterobacteria, and is very stable to destructive action of -lactamases. It also can be accumulated in tissues, providing high concentration of active substance in inflammation nidus. The therapeutic dose of the drug for adults is 400 mg/day. Ceftibuten is recommended and effectively used in pediatric practice in treatment of tonsillopharyngitis and otitis.
About the Authors
S. A Karpishchenko
St. Petersburg State I.P. Pavlov Medical University
Russian Federation
Sergei Anatol'evich Karpishchenko, PhD, professor, Head of the Department of Otolaryngology of academician I.P. Pavlov St. Petersburg State Medical University
Russian Federation
Sergei Anatol'evich Karpishchenko, PhD, professor, Head of the Department of Otolaryngology of academician I.P. Pavlov St. Petersburg State Medical University
E. B. Katinas
St. Petersburg State I.P. Pavlov Medical University
Russian Federation
Russian Federation
N. A. Shumilova
St. Petersburg State I.P. Pavlov Medical University
Russian Federation
Russian Federation
References
1. Мальцева Г. С. Системная антибактериальная терапия при хроническом тонзиллите. Российская оториноларингология. 2009; 3 (40): 149–156.
2. Гаращенко Т. И., Богомильский М. Р. Макролиды в терапии острого тонзиллита и его осложнений у детей. Методические рекомендации. М.: РГМУ. 1999. С. 28.
3. Гаращенко Т. И., Богомильский М. Р., Шишмарева Е. В. Новые подходы к лечению обострений хронического тонзиллита у детей. Детские инфекции. 2004; 1.
4. Пальчун В. Т. Развитие проблемы хронического тонзиллита. Вестник оториноларингологии. 2006; 6: 7–8.
5. Овчинников А. Ю., Сыркин А. Л., Габедава В. А. и др. Место антибактериальной терапии в попытке стандартизации лечения больных хроническим тонзиллитом и коморбидной миокардио- патией. Рос. оторинолар. Прил. 2007; 497–502.
6. Мальцева Г. С. Особенности стрептококковой инфекции при хроническом тонзиллите. Consilium Medicum. 2010; 12 (11).
7. LaPenta D. et al. Group A streptococci efficiently invade human respiratory epithelial cells. Proc. Natl. Acad. Sci. USA. 1994; 91 (25): 12115–12119.
8. Lilja M., Raisanen S., Stenfors L. E. Initial events in the pathogenesis of acute tonsillitis caused by Streptococcus pyogenes. Int. J. Pediatr Otorhinolaryngol. 1998; 45 (1): 15–20.
9. Park H. S. et al. Membranous cells in nasal-associated lymphoid tissue: a portal of entry for the respiratory mucosal pathogen group A streptococcus. J. Immunol. 2003; 171: 2532–2537.
10. Post J. C. Laryngoscope. 2001; 111: 2083–2094.
11. Страчунский Л. С., Каманин Е. И., Тарасов А. А. Влияние анти- биотикорезистентности на выбор антимикробных препаратов в оториноларингологии. Журн. ушн. нос. и горл. болезни. 2002; 5: 83–91.
12. Daly K. A., Brown J. E., Lindgren B. R. et al. Epidemiology of otitis media onset by six months of age. Pediatrics. 1999; 103: 1158–1166.
13. Healy G. B. Otitis media and middle ear effusions. In: Ballenger J. J., Snow J. B., Ed. Otorhinolaryngology: Head and Neck Surgery. 15th edition. Baltimore: Williams &Wilkins. 1996. Р. 1003–1009.
14. Bergeron M. G., Ahroheim C., Richard J. E. et al. Comparative effi cacies of erythromycin–sulfisoxazole and cefaclor in acute otitis media: a double blind randomized trial. Pediatr Infect Dis J. 1987; 6: 654–660.
15. Chole R. A., Faddis B. T. Arch. Otolaryngol. Head Neck Surg. 2002; 128: 1129–1133.
16. Raynen M. G., Zhang Y., Gorry M. C. et al. JAMA. 1998; 279: 296–299.
17. Jacoby G. A., Carreras I. Activities of beta-lactam antibiotics against Escherichia coli strains producing extended spectrum betalactamases. Antimicrob Agents Chemother. 1990; 34 (5): 858–862.
18. Kusers A., Crowe S. M., Grayson M. L. et al. The use of antibiotics. Clinical review of antibacterial, antifungal and antiviral drugs. 5th. ed.
19. Falck G., Grahn-Hakansson E., Holm S. E. et al. Acta. Otolaryngol. 1999; 119 (8): 944–948.
20. Буданов С. В. Цефтибутен (Цедекс) — новый цефалоспо- рин III поколения для приема внутрь: значение в терапии бактери- альных инфекций. Антибиотики и химиотерапия. 1998; 4: 33–39.
21. Brismar B., Edlund C., Nord C. E. Effect of ceftibuten on the normal intestinal microflora. Infect. 1993; 21: 373–375.
Review
For citations:
Karpishchenko S.A., Katinas E.B., Shumilova N.A. ORAL III GENERATION CEPHALOSPORIN CEFTIBUTEN IN TREATMENT OF ACUTE TONSILLOPHARYNGITIS AND OTITIS. Current Pediatrics. 2012;11(2):146-150. (In Russ.) https://doi.org/10.15690/vsp.v11i2.228
Views:
1347
Email this article 
